相关实验视频
Updated: May 7, 2026
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.3K
确定与EMT相关的亚型和9个基因的特征预测了骨髓瘤的预后
Feng Zhou1, Xuezheng Xu1, Yi Luo1
1Department of Orthopedics, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan Province, P. R. China.
Connective tissue research
|September 4, 2025
概括
这项研究确定了两种与上皮介质转变 (EMT) 相关的骨肉瘤亚型,具有不同的免疫特征. 一个9基因模型准确地预测患者的预后,
科学领域:
- 癌症学
- 分子生物学
- 生物信息学
背景情况:
- 骨肉瘤是儿童和青少年的高度恶性骨瘤,容易转移和复发.
- 表皮-介质细胞转换 (EMT) 是瘤转移的一个关键过程,增强细胞迁移和侵入.
- 了解分子亚型及其免疫微环境对于骨髓瘤治疗至关重要.
研究的目的:
- 在骨肉瘤中识别EMT相关的分子亚型.
- 分析与这些亚型相关的免疫微环境.
- 开发基于基因的骨肉瘤预后风险模型.
主要方法:
- 从TARGET数据库中检索骨肉瘤基因表达和临床数据.
- 应用共识聚类来确定与EMT相关的分子亚型.
- 使用ESTIMATE算法进行免疫微环境评估和WGCNA进行共表达网络分析.
- 使用拉索-考克斯回归来构建和验证9基因预后风险模型.
主要成果:
- 确定了两种不同的分子亚型 (C1和C2),具有不同的临床结果和免疫评分.
- 通过WGCNA,PINK模块与已识别的亚型有显著的关联.
- 一个9基因预测模型 (EPHB3,GADD45GIP1,RAD23A,NGDN,SYCE2,SCD,AP1M1,POLR3D,FADS2) 显示出高的预测准确度.
- GADD45GIP1,NGDN,AP1M1和POLR3D被确定为独立的预后因素.
结论:
- 发现了两种与EMT相关的骨肉瘤亚型,具有不同的免疫特征,可能指导临床策略.
- 开发的9基因风险模型为预测骨肉瘤预后提供了可靠的工具.
- 对这些亚型和预后基因的进一步研究可能会改善患者的结果.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...